09:47 AM EST - Valeant Pharmaceuticals International : announced third-quarter financial results for 2013. Total revenue was $1.54 billion; an increase of 74% over the prior year. The Company reported a net loss of $973 million for the third quarter of 2013, or a loss of $2.92 per share. Valeant Pharmaceuticals International
shares T.VRX are trading down $2.15 at $112.20.
